Shock · DIC
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
1 finding from 1 review
Adverse events · DIC
1 finding from 1 review
Bleeding · DIC
It is very uncertain whether dermatan changes bleeding compared with heparin (very low certainty).
1 finding from 1 review
Resolution of respiratory failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Shock · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · DIC
It is very uncertain whether human activated protein C changes adverse events compared with heparin (very low certainty).
1 finding from 1 review
Bleeding · DIC
It is very uncertain whether human activated protein C changes bleeding compared with heparin (very low certainty).
1 finding from 1 review
Resolution of respiratory failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Shock · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall mortality · DIC
1 finding from 1 review
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
It is very uncertain whether recombinant human soluble thrombomodulin changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review